Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol
- 1 May 2016
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 27 (5), 795-800
- https://doi.org/10.1093/annonc/mdw018
Abstract
Next-generation sequencing in cancer research may reveal germline variants of clinical significance. We report patient preferences for return of results and the prevalence of incidental pathogenic germline variants (PGVs). Targeted exome sequencing of 202 genes was carried out in 1000 advanced cancers using tumor and normal DNA in a research laboratory. Pathogenic variants in 18 genes, recommended for return by The American College of Medical Genetics and Genomics, as well as PALB2, were considered actionable. Patient preferences of return of incidental germline results were collected. Return of results was initiated with genetic counseling and repeat CLIA testing. Of the 1000 patients who underwent sequencing, 43 had likely PGVs: APC (1), BRCA1 (11), BRCA2 (10), TP53 (10), MSH2 (1), MSH6 (4), PALB2 (2), PTEN (2), TSC2 (1), and RB1 (1). Twenty (47%) of 43 variants were previously known based on clinical genetic testing. Of the 1167 patients who consented for a germline testing protocol, 1157 (99%) desired to be informed of incidental results. Twenty-three previously unrecognized mutations identified in the research environment were confirmed with an orthogonal CLIA platform. All patients approached decided to proceed with formal genetic counseling; in all cases where formal genetic testing was carried out, the germline variant of concern validated with clinical genetic testing. In this series, 2.3% patients had previously unrecognized pathogenic germline mutations in 19 cancer-related genes. Thus, genomic sequencing must be accompanied by a plan for return of germline results, in partnership with genetic counseling.Funding Information
- Cancer Prevention Research Institute of Texas (RP150535)
- NCI (U01CA180964)
- NCI (R01 CA172652)
- NCATS (UL1 TR000371)
- Center for Clinical and Translational Sciences
- Bosarge Foundation
- Nellie B Connally Breast Cancer Research Fund
- MD Anderson Cancer Center
- NIH
- NCI (P30 CA016672)
- Cancer Prevention Research Institute of Texas (RP150535)
- NCI (U01CA180964)
- NCI (R01 CA172652)
- NCATS (UL1 TR000371)
- Center for Clinical and Translational Sciences
- Bosarge Foundation
- Nellie B Connally Breast Cancer Research Fund
- MD Anderson Cancer Center
- NIH
- NCI (P30 CA016672)
This publication has 20 references indexed in Scilit:
- Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNAJAMA Oncology, 2016
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialThe Lancet, 2010
- Multiple endocrine neoplasia type 2RETprotooncogene database: Repository of MEN2-associatedRETsequence variation and reference for genotype/phenotype correlationsHuman Mutation, 2009
- Ethical, Legal, and Social Implications of Biobanks for Genetics ResearchAdvances in genetics, 2008
- Pharmacogenetics of warfarin: regulatory, scientific, and clinical issuesJournal of Thrombosis and Thrombolysis, 2007
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- Reporting genetic results in research studies: Summary and recommendations of an NHLBI working groupAmerican Journal of Medical Genetics Part A, 2006
- Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.Drug Metabolism and Disposition, 2003
- The Breast Cancer Information Core: Database design, structure, and scopeHuman Mutation, 2000
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences of the United States of America, 1971